直接凝血酶抑制剂比伐卢定的研究现状

比伐卢定在2000年经美国食品药品管理局批准上市,是直接的、特异的、可逆的凝血酶抑制剂,具有抗凝效果的可预测性、不诱导血小板减少及对纤维蛋白结合的凝血酶有效等优势,克服了肝素、水蛭素的局限性。本文对其药理学特点、药效学与药代动力学、药物相互作用、临床应用与不良反应等进行简要综述。

Advances in search for bivalirudin as a direct inhibitor of thrombin

Bivalirudin was approved by US Food and Drug Administration as a new direct inhibitor of thrombin in 2000.The anticoagulant effect of bivalirudin can be predicted.Drug induced thrombocytopenia does not occur after administration of bivalirudin.It overcomes the limitations of heparin and hirudin.The pharmacology characteristics,action mechanism,pharmacokinetics,drug interactions and clinical uses of bivalirudin were overviewed.